| SGLT2 Inhibitor |
0 |
1 |
| Type 2 Diabetes Mellitus |
0 |
0.88 |
| Heart Failure (HF) |
0 |
0.99 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.98 |
| Heart |
0 |
0.42 |
| Cardiovascular Risk Management |
0 |
0.31 |
| Hospital |
0 |
0.19 |
| Cerebrovascular Accident |
0 |
0.18 |
| Infarction |
0 |
0.12 |
| Myocardial Infarction (MI) |
0 |
0.11 |
| Clinical Guidelines |
0 |
0.08 |
| Cardiovascular disease |
0 |
0.04 |
| Florida |
0 |
0.04 |
| Meta-Analysis |
0 |
0.04 |
| Patient History |
0 |
0.04 |
| Pharmacoepidemiology |
0 |
0.04 |
| Receptors |
0 |
0.04 |